Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[2-hydroxy-1-indanyl]-5-[(2-tertiarybutylaminocarbonyl)-4(benzo[1,3]dioxol-5-ylmethyl)-piperazino]-4-hydroxy-2-(1-phenylethyl)-pentanamide
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
This compound is an experimental small molecule analogue of the HIV protease inhibitor indinavir. It was designed to overcome resistance in multi-drug-resistant HIV by introducing two key modifications to the indinavir scaffold: a methylenedioxyphenyl group at the P₂' position and an S-methyl group at the P₁ benzylic position. These changes aim to enhance binding affinity and efficacy against resistant variants of HIV protease. The compound has been studied structurally and biochemically in complex with mutant forms of HIV protease but has not advanced beyond preclinical or early research stages[5][6]. There are no approved indications or clinical trials for this molecule.
- Other names
- (2S)-4-(1,3-Benzodioxol-5-ylmethyl)-1-[(2S,4S,5S)-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-ind en -1 - yl]carbamoyl}-5-ph en ylhexyl]-N-( 2-m eth yl - 2-propanyl ) - 2-piperazinecarboxamideN-( 2-hydroxy - 1-indanyl ) - 5 -( ( 2-tertiarybutylaminocarbonyl ) -4( benzo( 1 ,3)dioxol–5– ylmethyl) – piperazino) –4–hydroxy– 2 – ( 1 – phenylethyl ) – pentanamide
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on N-[2-hydroxy-1-indanyl]-5-[(2-tertiarybutylaminocarbonyl)-4(benzo[1,3]dioxol-5-ylmethyl)-piperazino]-4-hydroxy-2-(1-phenylethyl)-pentanamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-[2-hydroxy-1-indanyl]-5-[(2-tertiarybutylaminocarbonyl)-4(benzo[1,3]dioxol-5-ylmethyl)-piperazino]-4-hydroxy-2-(1-phenylethyl)-pentanamide.